MiNK Therapeutics
INKT
27 hedge funds and large institutions have $2.39M invested in MiNK Therapeutics in 2026 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
79% more capital invested
Capital invested by funds: $1.34M → $2.39M (+$1.05M)
17% more funds holding
Funds holding: 23 → 27 (+4)
1.4% more ownership
Funds ownership: 2.7% → 4.1% (+1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DnB Asset Management
Oslo,
Norway
|
+$642K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$180K |
| 3 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$108K |
| 4 |
BlackRock
New York
|
+$83.6K |
| 5 |
US Bancorp
Minneapolis,
Minnesota
|
+$23.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$120K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$20.6K |
| 3 |
AGWCA
Annis Gardner Whiting Capital Advisors
Tampa,
Florida
|
-$2.11K |
| 4 |
Citigroup
New York
|
-$958 |
| 5 |
PWPS
Pinnacle Wealth Planning Services
Mansfield,
Ohio
|
-$53 |
INKT Hedge Fund Activity: Q2 2026 in Review
27 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q2 2026, worth a combined $2.39M — up 79% from $1.34M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new INKT positions and 3 closed out — a net gain of 4 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was DnB Asset Management, opening a new position worth an estimated $642K. The largest seller was UBS Group, cutting an estimated $120K.
- 27 institutional investors held MiNK Therapeutics (INKT) as of Q2 2026, up from 23 in Q1 2026.
- Funds reported $2.39M of MiNK Therapeutics stock for Q2 2026, up 79% quarter-over-quarter.
- 7 funds opened new MiNK Therapeutics positions in Q2 2026 and 3 closed out, a net change of +4 holders.
- The largest MiNK Therapeutics buyer in Q2 2026 was DnB Asset Management, an estimated $642K added.
- The largest MiNK Therapeutics seller in Q2 2026 was UBS Group, an estimated $120K sold.
Based on aggregated 13F filings for Q2 2026.